Cleared Traditional

K132663 - I-QARE DS-W BLOOD GLUCOSE MONITORING SY...

K132663 is the FDA 510(k) clearance for I-QARE DS-W BLOOD GLUCOSE MONITORING SY... by Alliance International Co., Ltd.. It is a Class 2 Chemistry device (product code NBW) cleared through the Traditional 510(k) pathway after a 602-day FDA review.

K132663 · Alliance International Co., Ltd. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Apr 2015
Decision
602d
Days
Class 2
Risk

K132663 is an FDA 510(k) clearance for the I-QARE DS-W BLOOD GLUCOSE MONITORING SYSTEM. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Alliance International Co., Ltd. (New Taipei City, 239, TW). The FDA issued a Cleared decision on April 20, 2015 after a review of 602 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: High-complexity regulatory submission. Elevated predicate reliance profile. The extended review timeline suggests the FDA required additional documentation before confirming substantial equivalence - a pattern common in complex or first-of-kind Chemistry submissions.

View all Alliance International Co., Ltd. devices

Submission Details

510(k) Number K132663 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received August 26, 2013
Decision Date April 20, 2015
Days to Decision 602 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
514d slower than avg
Panel avg: 88d · This submission: 602d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 236
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K132663.
FreeStyle Freedom Lite Blood Glucose Monitoring System
K150531 · Abbott Laboratories · Jun 2015
FORA GD43 Blood Glucose Monitoring System
K143467 · Taidoc Technology Corporation · May 2015
BGM009 BLOOD GLUCOSE MONITORING SYSTEM
K141036 · Apex BioTechnology Corp. · May 2015
ACCU-CHEK AVIVA CONNECT BLOOD GLUCOSE MONITORING SYSTEM
K141867 · Roche Diagnostics · Mar 2015
FREESTYLE PRECISION NEO BLOOD GLUCOSE: MONITORING SYSTEM, TEST STRIPS (50CT), TEST STRIPS (100CT)
K140371 · Abbott Diabetes Care, Inc. · Sep 2014
ACCU-CHEK Performa Blood Glucose Monitoring System
K133741 · Roche Diagnostics · Aug 2014